GLP 3 Retatrutide 20mg

What It Is

Retatrutide is a single peptide molecule engineered to stimulate three key metabolic hormone receptors:

● GIP receptor — enhances insulin secretion and metabolic regulation.

● GLP-1 receptor — reduces appetite, slows gastric emptying, and improves glucose control.

● Glucagon receptor — increases energy expenditure and fat oxidation.

This combination is intended to produce deeper weight-loss effects than single- or dual-agonist drugs like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound). 

How It Works

Core Mechanism: Triple-Receptor Activation

Retatrutide (LY3437943) binds to and activates:

● GIP receptors — improves insulin sensitivity and metabolic flexibility; enhances the body’s ability to handle nutrients.

● GLP-1 receptors — suppresses appetite, slows gastric emptying, and improves glucose control.

● Glucagon receptors — increases energy expenditure and promotes fat oxidation.

Together, these pathways create a multi-pronged metabolic shift that reduces calorie intake andincreases calorie burn. 

What Each Pathway Contributes

1. GLP-1: Appetite & Satiety Control

● Reduces hunger signals in the brain.

● Slows stomach emptying, helping you feel full longer.

● Improves insulin secretion in a glucose-dependent way. 

2. GIP: Insulin Sensitivity & Fat Distribution

● Enhances insulin response to meals.

● May shift fat storage away from visceral depots.

● Works synergistically with GLP-1 to reduce food intake. 

3. Glucagon: Energy Expenditure & Fat Burning

● Increases resting energy expenditure (thermogenesis).

● Promotes lipolysis and fat oxidation.

● Helps counterbalance the reduced metabolic rate that often accompanies weight loss. 

How These Pathways Interact

Retatrutide’s design intentionally balances these three hormones:

● GLP-1 and GIP reduce appetite and improve glucose handling.

● Glucagon increases energy burn, preventing metabolic slowdown.

● The combination produces greater weight loss than GLP-1 or GIP/GLP-1 agonists alone.

Phase 2 trials showed up to 24.2% weight loss at 48 weeks, one of the highest reductions seen in any obesity drug to date. 

Additional Physiological Effects

● Delayed gastric emptying, reducing post-meal glucose spikes.

● Improved liver fat metabolism, with early evidence of benefit in MASLD/MASH.

● Dose-dependent GI side effects, similar to other incretin drugs. 

Why It’s Considered a “Next-Generation” Metabolic Drug

Retatrutide is the first medication to combine all three incretin-related pathways into one molecule. This allows it to:

● Reduce appetite

● Improve insulin sensitivity

● Increase energy expenditure

● Promote fat oxidation

● Improve metabolic markers across multiple systems

This multi-axis approach is why researchers describe it as potentially transformational in obesity and metabolic disease treatment.

Benefits

1. Exceptional Weight Loss

● Phase 3 TRIUMPH-4 participants lost up to 28.7% of body weight (≈71 lbs) at 68 weeks. 

● Phase 2 trials showed up to 24.2% weight loss at 48 weeks. This is the highest weight reduction reported for any obesity medication to date.

2. Major Improvements in Knee Osteoarthritis Pain

● In TRIUMPH-4, retatrutide reduced WOMAC pain scores by up to 75.8%.

● More than 1 in 8 patients became completely pain-free by week 68. This is a unique benefit not seen with other incretin drugs.

3. Strong Metabolic Improvements

Phase 2 data show improvements in:

● Blood sugar control (HbA1c)

● Triglycerides and LDL cholesterol

● Inflammatory markers (hsCRP)

● Blood pressure (up to −14 mmHg systolic at high dose)

These changes suggest broad cardiometabolic protection.

4. Dramatic Reduction in Liver Fat

● Exploratory analysis showed up to an 86% reduction in liver fat at 24 weeks at higher doses. This positions retatrutide as a potential therapy for MASLD/MASH.

5. Increased Energy Expenditure

Because it activates the glucagon receptor, retatrutide:

● Raises resting energy expenditure

● Promotes fat oxidation

● Helps counteract metabolic slowdown during weight loss This is a key differentiator from semaglutide or tirzepatide.

6. Appetite Suppression and Satiety

Through GLP-1 and GIP pathways, retatrutide:

● Reduces hunger

● Slows gastric emptying

● Lowers overall caloric intake

7. Potential Benefits in Multiple Conditions Under Study

Retatrutide is being evaluated for:

● Type 2 diabetes

● Obstructive sleep apnea

● Chronic low back pain

● Cardiovascular and renal outcomes

● Knee osteoarthritis

● MASLD/MASH

What the Science Shows

Evidence base

● Main data source: Phase 2 randomized, placebo-controlled trial in adults with obesity/overweight, published in NEJM in 2023. 

● Additional summaries and expert commentary confirm the magnitude of effect and dose–response pattern. 

Weight-loss efficacy

● At the highest dose (12 mg weekly), participants lost 24.2% of body weight at 48 weekson average. 

● Weight loss was dose-dependent (roughly −17.1%, −22.8%, −24.2% at 4, 8, 12 mg at 48 weeks). 

● A very high proportion achieved large reductions:

o ≥15% weight loss in ~93% of people on 12 mg

o ≥20% weight loss in ~63% on 12 mg 

This places retatrutide at or near the top of all obesity drugs studied so far in terms of absolute weight loss.

Metabolic and organ-level effects

● Glycemic control: In people with obesity and type 2 diabetes, retatrutide reduced both HbA1c and body weight significantly vs placebo. 

● Lipids & blood pressure: Phase 2 data show improvements in triglycerides, LDL, and meaningful drops in systolic blood pressure (up to ~−14 mmHg at higher doses). 

● Liver fat: Exploratory analyses report large reductions in liver fat content (up to ~80–86%) at higher doses, suggesting strong potential in MASLD/MASH. 

Overall, the science points to a broad cardiometabolic benefit profile, not just weight loss.

Reconstitution

What You’ll Need

● 20 mg retatrutide vial (lyophilized)

● Bacteriostatic water (BAC water) – preferred for multi-dose use

● 1–3 mL syringe (for adding BAC water)

● Insulin syringes (for dosing)

● Alcohol prep pads

Add 2ml BAC water slowly down the side of the vial.  

Dosing Protocol

Standard Conservative Titration (Most Tolerable)

Weeks

Weekly Dose

1st week

5units M W F

2nd week

10units M W F

3rd week 

15units M W F 

hold at 15 units 

Notes:

● Many individuals experience strong appetite suppression by 2–4 mg.

● Clinical trial data has explored doses up to 12 mg weekly.

● Not everyone tolerates 8–12 mg.

Expected Effects by Dose Range

0.5–1 mg

● Mild appetite reduction

● Early satiety

● Minimal glucagon effect

2–4 mg

● Strong appetite suppression

● Noticeable fat loss

● Possible nausea if calories too low

6–8 mg

● Aggressive fat loss

● Increased thermogenesis

● Higher GI side-effect risk

10–12 mg

● Clinical trial–level dosing

● Significant weight reduction

● Highest side-effect burden

Precautions

•  Nausea

•  Delayed gastric emptying

•  Reflux

•  Constipation

•  Elevated heart rate (glucagon effect)

•  Hypoglycemia (if combined with insulin/other agents)

How to be Successful

Start Lower Than You Think

Most failures come from titrating too fast.

Best practice:

● 0.5 mg 1st week 

● Only go up if needed 

● Stay at the lowest effective dose

You do not get better fat loss by racing to 8–12 mg if you can’t eat, train, or recover.

Protein Is Non-Negotiable

Retatrutide suppresses appetite aggressively.

If protein drops, you lose lean mass.

Target:

● 0.7–1.0 g protein per lb of goal bodyweight

● Split across 3–4 smaller meals

If appetite is low:

● Lean meats

● Greek yogurt

● Protein shakes

● Bone broth + collagen

Lift Weights (Glucagon = Catabolic Risk)

The glucagon receptor activation increases energy expenditure but can increase muscle breakdown if protein and resistance training are low.

Minimum effective plan:

● 3–4 resistance sessions weekly

● Focus on compound lifts

● Keep strength stable or improving

If strength crashes, dose may be too high.

Manage GI Side Effects Proactively

Most common:

● Nausea

● Constipation

● Reflux

● Early fullness

Prevention strategy:

● Smaller meals

● Avoid high-fat + high-volume meals

● Hydrate aggressively

● Add electrolytes

● Magnesium citrate or glycinate at night (if constipation)

Do Not Undereat Severely

Retatrutide can make 800–1000 calories feel “easy.”

That will:

● Tank metabolism

● Increase fatigue

● Increase hair shedding

● Flatten hormones

Safer deficit:

● 300–700 calorie deficit

● Not starvation

Monitor These Metrics Weekly

● Morning bodyweight

● Waist measurement

● Resting heart rate (glucagon can raise it)

● Strength in 3 key lifts

● Energy levels

If resting HR increases >10 bpm persistently → reassess dose.

Cycle or Hold?

Many experienced users:

● Titrate to 2–6 mg

● Hold at effective dose

● Avoid pushing to 10–12 mg unless medically supervised

More is not better long term.

Who Struggles Most?

● People who chase appetite suppression instead of fat loss

● People who stop lifting

● People who jump doses every 2 weeks

● People who stack multiple incretins simultaneously

Mental Strategy

Retatrutide removes food noise.
Use that window to build:

● Consistent meal timing

● Portion awareness

● Training habit

● Sleep schedule

When you eventually taper, habits matter more than the drug.

Red Flags

Stop and reassess if you notice:

● Persistent vomiting

● Severe abdominal pain

● Sustained high heart rate

● Extreme fatigue

● Signs of gallbladder distress

The Bottom Line

Success with retatrutide is about:
Low dose + protein + resistance training + slow titration + metabolic monitoring.

FAQs

Mechanism: How is it different?

● Semaglutide → GLP-1 receptor agonist

● Tirzepatide → Dual GIP + GLP-1 receptor agonist

● Retatrutide → GLP-1 + GIP + glucagon receptor agonist

The glucagon receptor activity:

● Increases hepatic glucose output (mild)

● Increases energy expenditure

● Raises resting heart rate (dose-dependent)

● May enhance lipolysis

● Can increase catabolic signaling if nutrition is insufficient

This is why retatrutide often produces greater total weight loss in trials compared to dual agonists.

Typical Dosing Range

Clinical studies evaluated:

● 1 mg → 12 mg once weekly

Common effective range in practice:

● 2–6 mg weekly

Higher doses:

● Increase nausea incidence

● Increase resting HR

● Increase fatigue risk

● Increase lean mass loss risk if unmanaged

Onset Timeline

Effect

Typical Onset

Appetite suppression

3–7 days

Early weight drop (water + glycogen)

1–2 weeks

Visible fat loss

4+ weeks

Peak metabolic acceleration

8–12 weeks

Full physiologic adaptation

3–6 months

The early drop is often glycogen depletion, not pure fat.

Most Common Side Effects

● Nausea

● Constipation

● Reflux

● Early satiety

● Mild tachycardia

● Fatigue (especially with aggressive caloric restriction)

Severity strongly correlates with:

● Dose

● Speed of titration

● Meal size

● Fat intake

Does It Burn Muscle?

Not directly — but indirectly possible.

Risk factors:

● Protein <0.7 g/lb goal bodyweight

● No resistance training

● 800–1,000 kcal deficit

● High-dose exposure

Glucagon receptor activation increases metabolic output. Without anabolic stimulus, lean mass loss risk rises.

Mitigation:

● Lift 3–4x weekly

● High protein

● Moderate deficit

Heart Rate Effects

Average increase: 3–10 bpm

Concerning if:

● Sustained >10–15 bpm increase

● Palpitations

● Symptomatic tachycardia

Monitor:

● Weekly resting HR

● Blood pressure

Hypoglycemia Risk

Low when used alone.

Higher risk if combined with:

● Insulin

● Sulfonylureas

● Severe caloric restriction

The glucagon component generally protects somewhat against hypoglycemia compared to GLP-1 alone, but medication stacking changes risk profile.

Duration of Use

Long-term human data is still limited (investigational drug).

Common structured approach:

● Titrate to effective dose

● Maintain 3–6 months

● Reassess body composition, labs, HR

● Consider taper rather than abrupt stop

High-dose indefinite use should be medically supervised.

Stacking With Other Incretins

Not advised with:

● Semaglutide

● Tirzepatide

Mechanistic redundancy:

● Increased GI burden

● Elevated hypoglycemia risk

● Increased HR

There is no clear metabolic benefit to stacking.

Thyroid Risk

Like other GLP-1–based drugs:

Avoid if:

● Personal or family history of medullary thyroid carcinoma

● MEN2 syndrome

Rodent C-cell tumor findings led to this precaution.

What Happens When You Stop?

Common:

● Appetite rebound

● Glycogen + water regain

● Some fat regain if caloric discipline isn’t maintained

Best practice:

● Taper gradually

● Increase dietary structure before stopping

● Maintain resistance training

Who Should Avoid It?

● History of pancreatitis

● Severe gastroparesis

● Active gallbladder disease

● MEN2 / medullary thyroid carcinoma

● Uncontrolled tachyarrhythmia

Availability

Research grade Teriparatide is available at www.turawellness.com